Alzheimer's Disease Related Antibodies

Alzheimer's disease (AD), the most common type of dementia, is projected to triple in prevalence by 2050, posing a major worldwide health concern with significant implications for individuals and society. The initial symptoms of AD are insidious, progressive problems centered on episodic memory. The criteria for amnestic-moderate cognitive impairment (MCI) may be met at this point. Memory challenges, loss of confidence, and difficulties multitasking follow. Cognitive impairments become severe and pervasive as the condition progresses, even interfering with regular life tasks. At this time, patients can be diagnosed with Alzheimer's disease dementia.

Key Factors of AD

The key pathology characteristic features of AD are amyloid plaques and neurofibrillary tangles (NFT). Additionally, there are also neuronal threads, neuroinflammation, dystrophic neurites, astrogliosis, and microglial activation. Amyloid plaques in the brain Vascular disorders usually coexist. Neurodegeneration, synaptic and neuronal loss, and macroscopic atrophy are all downstream effects of these pathogenic processes. Genes related to AD are shown in Figure 1. In addition to Aβ, Tau, PSEN, APOE, TREM2, and TDP-43 are all popular antibody targets in Alzheimer's disease research.

Fig.1 An overview of genes that have been implicated in Alzheimer's disease.¹

Important Targets Related to AD

Creative Biolabs supplies an array of antibodies for AD research to assist scientists with clarifying the etiology of the disease and slowing its progression. Antibodies are a workhorse technique in neuroscience research, with applications including Western blotting, immunofluorescence, ELISA, flow cytometry, and immunoprecipitation.

If you'd like to learn more about AD-related antibodies, please click on the related products below or contact us directly, and we'll get back to you as soon as possible.

Reference

1. Lane, C A et al. “Alzheimer's disease.” European journal of neurology vol. 25,1 (2018): 59-70.